A toxicity study of eltenac, a nonsteroidal anti‐inflammatory drug, in horses

Publisher Website
Google Scholar
Abstract
A double-blind study was performed, in horses, to determine the potential toxic effects of the nonsteroidal anti-inflammatory drug, eltenac(4-[(2,6-dichlorophenyl) amino]-3-thiopheneacetic acid). Four treatment groups of six horses were formed. The drug was injected intravenously, once daily, at a dose level of 0.5 mg/kg, 1.5 mg/kg or 2.5 mg/kg for 15 days. A control group was injected with sterile saline solution. Horses were monitored for changes in appetite, physical examinations, biochemical evaluations and gastroscopic examinations. Complete post-mortem examinations were also performed. A few glandular gastric ulcers, mild in severity, developed in seven animals during the treatment period. This occurred more often in horses treated with high doses of eltenac (P = 0.02). A dose-dependent change of white blood cell (WBC) count and neutrophil count was noted. Total protein, albumin and globulin levels had dose-dependent decreases. One horse in the high dose group (2.5 mg/kg) developed ventral ooedema as well as hypoproteinaemia. Gross post-mortem and histological examination did not reveal any signs of drug related gastrointestinal, renal or hepatic abnormalities. Toxic effects of eltenac given intravenously were greatest in horses treated with 2.5 mg/kg of the compound for 15 days compared to other groups.